Beta Pharma, Inc.

Lexicon Pharmaceuticals, Inc.

Novartis Ag

Bristol-myers Squibb Compnay

Other

Beta Pharma (shanghai) Co., Ltd.

Michael Alan Green

Michael Nicholas Greco

Don Zhang

Jirong Peng

Michael John Costanzo

Yulian Zhang

Yingzhi Bi

Victoria Lynn Wilde

Kenneth Gordon Carson

Giovanni Cianchetta

Godwin Kwame Kumi

John E Macor

Joanne J Bronson

Stacy W Remiszewski

Carolyn Diane Dzierba

Richard William Versace

Lawrence Blas Perez

Kenneth Walter Bair

Sushil Kumar Sharma

Lidia Cristina Sambucetti

Alan Main

David Kimball

Soojin Kwon

Greg Zipp

Godwin Kumi

Cynthia Anne Fink

Gregory Glenn Zipp

Richard A Hartz

Vijay T Ahuja

Li Dong

Jiancheng Wang

S Roy Kimura

Ying Jade Liu

Michael Walter Gardyan

Lidia Sambucetti

Glenn Gregory Zipp

Zhi Liang

Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatment of EGFR mutant-related cancers are disclosed:

Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors

The present disclosure provides [1,2,4]triazolo[4,3-b][1,2,4]triazine, [1,2,4] triazolo[4,3-b]pyridazine, and [1,2,3]triazolo[4,5-b]pyrazine derivatives, and pharmaceutically acceptable salts, solvates or prodrugs thereof, as tyrosine kinase c-MET inhibitors, which are useful as novel anticancer and/or anti-inflammatory agents.

Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof

A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGER), such as various cancers, are disclosed.

Pharmaceutical formulations of-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof

This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.

Substituted 2-anilinopyrimidine derivatives as EGFR modulators

A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.

Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof

Methods of using substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, or compositions, for the treatment of brain cancers, in particular EGFR-mediated metastatic brain cancer, are disclosed.

2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers

Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.

Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

Pagoda dragon soap tower

Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R, Rand Rare defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Pagoda soap tower

Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R, Rand Rare defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by adaptor associated kinase 1 activity are also disclosed.

Pet safety light

Exercise apparatus

Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R, Rand Rare defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use

Growing community of inventors

Easton, PA, United States of America

Michael Alan Green